Please ensure Javascript is enabled for purposes of website accessibility

Why Genetic Screening Stock Invitae Skyrocketed 16.4% in March

By Todd Campbell – Apr 4, 2019 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's making progress in its goal to make genetic screening for healthcare available to everyone.

What happened

After reporting soaring sales in February and successfully bolstering its balance sheet through a secondary stock offering in March, Invitae Corporation's (NVTA 1.15%) share price shot up 16.4% last month, according to S&P Global Market Intelligence.

So what

Advances in genomics are allowing researchers to develop increasingly precise treatments for complex diseases, including cancer, and that's sparking demand for genetic screening services that offer insight into patients' genetic makeup.

A double helix of DNA within a test tube.

Image source: Getty Images.

The growing demand for genetic screening, especially in cancer, prenatal, and neonatal markets, is fueling impressive financial results at Invitae.

On Feb. 19, the company announced its genetic testing volume had more than doubled to 303,000 in 2018, resulting in full-year revenue of $148 million, up 117% from 2017. In the fourth quarter, revenue was $45.4 million, up 78.6% from Q4 2017.

Invitae's cost per test declined by over 20% in 2018, resulting in gross margins of 53% in the fourth quarter and 46% for the full year. For perspective, gross margin was 27% in 2017.

On the heels of its results, management completed a secondary stock offering on March 8 that was fully subscribed, including an underwriter's option to purchases additional shares. In total, Invitae placed 10.35 million shares, generating $196.7 million in proceeds, excluding fees, for its balance sheet.

Now what

It's early innings for genetic screening, so this additional financial flexibility will come in handy as Invitae invests heavily to establish leadership. The company's improving revenue and gross margin suggest progress is being made toward profitability, but Invitae's still losing money every quarter, and that's likely to continue for a while.

Nevertheless, the company expects genetic test volume to exceed 500,000 in 2019, resulting in revenue reaching $220 million, up 48% from 2018. If the company can continue delivering that kind of growth, it's likely only a matter of time before it can reward investors with earnings. 

Todd Campbell owns shares of Invitae. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
Invitae
NVTA
$2.64 (1.15%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.